Table 3.
Genetic and clinical features of the two VHL patient groups
| aRTL ≤ 0.44 | aRTL > 0.44 | P value | |
|---|---|---|---|
| N (%) | N (%) | ||
| Sex | |||
| Male | 42 (45.7%) | 49 (53.3%) | 0.302 |
| Female | 50 (54.3%) | 43 (46.7%) | |
| Family historya | |||
| Yes | 77 (88.5%) | 60 (77.9%) | 0.068 |
| No | 10 (11.5%) | 17 (22.1%) | |
| Mutation | |||
| Missense | 50 (54.3%) | 43 (46.7%) | 0.302 |
| Truncating | 42 (45.7%) | 49 (53.3%) | |
| Originb | |||
| Paternal | 30 (40.5%) | 18 (36.7%) | 0.672 |
| Maternal | 44 (59.5%) | 31 (63.3%) | |
| Total | 92 | 92 | – |
aRTL, age‐adjusted relative telomere length.
a
20 patients have an unknown family history.
b
61 patients have an unknown origin.